Inspiro Medical developments Inspiromatic™, a novel dry powder inhaler for the treatment of pulmonary diseases, multi-billion dollar market
Medical device company developing Inspiromatic™, a novel dry powder inhaler for the treatment of pulmonary diseases. The company successfully completed FIM trial in asthma patients. Inspiromatic™ enables improved lung drug deposition, monitor patient inhalation and real-time feedback interface. Inspiro is seeking an investment, to enhance its product development and engage global pharma companies in the development of drug-device formulation.